ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report) had its price target raised by stock analysts at Morgan Stanley from $15.00 to $16.00 in a research report issued on Thursday, Benzinga reports. The firm currently has an "equal weight" rating on the stock. Morgan Stanley's price target suggests a potential upside of 6.67% from the company's previous close.
ABIVAX Société Anonyme Price Performance
Shares of ABVX stock traded down $0.39 during trading hours on Thursday, hitting $15.00. The company's stock had a trading volume of 79,706 shares, compared to its average volume of 114,743. The stock has a fifty day moving average of $13.74. ABIVAX Société Anonyme has a twelve month low of $7.99 and a twelve month high of $17.02.
Hedge Funds Weigh In On ABIVAX Société Anonyme
Several hedge funds have recently bought and sold shares of the stock. Blackstone Inc. acquired a new stake in shares of ABIVAX Société Anonyme during the fourth quarter valued at $25,345,000. Commodore Capital LP purchased a new position in ABIVAX Société Anonyme in the 4th quarter valued at about $20,277,000. Great Point Partners LLC acquired a new stake in shares of ABIVAX Société Anonyme during the 4th quarter worth about $16,585,000. Franklin Resources Inc. purchased a new stake in shares of ABIVAX Société Anonyme during the fourth quarter worth about $13,630,000. Finally, Nantahala Capital Management LLC acquired a new position in shares of ABIVAX Société Anonyme in the fourth quarter valued at approximately $10,807,000. Hedge funds and other institutional investors own 47.91% of the company's stock.
About ABIVAX Société Anonyme
(
Get Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
Recommended Stories
Before you consider ABIVAX Société Anonyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABIVAX Société Anonyme wasn't on the list.
While ABIVAX Société Anonyme currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
